Heron Therapeutics Inc
AXD2
Company Profile
Business description
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Contact
100 Regency Forect Drive
Suite 300
CaryNC27518
USAT: +1 858 251-4400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
122
Stocks News & Analysis
stocks
The SpaceX IPO and the Elon Musk factor
Potential investors should remember that the company’s controlling shareholder can move markets with a few words.
stocks
The ASX’s most shorted stocks in 2026
What we can and can’t learn from the top 20 most shorted ASX shares.
stocks
ASX energy producers: Energy prices rise sharply as global tensions flare, but long-term view unchanged
Our view on the chaotic energy markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,657.50 | 2.20 | 0.03% |
| CAC 40 | 7,721.94 | 19.99 | 0.26% |
| DAX 40 | 22,346.12 | 45.37 | 0.20% |
| Dow JONES (US) | 45,165.80 | 794.31 | -1.73% |
| FTSE 100 | 10,060.67 | 93.32 | 0.94% |
| HKSE | 24,750.79 | 201.09 | -0.81% |
| NASDAQ | 20,948.36 | 459.72 | -2.15% |
| Nikkei 225 | 51,885.85 | 1,487.22 | -2.79% |
| NZX 50 Index | 12,748.92 | 186.47 | -1.44% |
| S&P 500 | 6,370.69 | 106.47 | -1.64% |
| S&P/ASX 200 | 8,461.00 | 0.10 | 0.00% |
| SSE Composite Index | 3,923.29 | 9.56 | 0.24% |